Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on November 20, 2015, 01:31:33 pm
-
Researchers in the ongoing Phase II, two-part SURVEYOR-II study are currently testing 8- and 12-week regimens of the NS3/4A protease inhibitor ABT-493 and the NS5A inhibitor ABT-530, with or without ribavirin, among people who were treatment naive or who had failed interferon-based treatment.
So far, results show mostly high cure rates among people with genotypes 2 and 3 of the virus.
For more information: http://www.hepmag.com/articles/SURVEYOR_II_2501_28069.shtml